Alalawi Ali, Albalawi Enas, Aljohani Abdullah, Almutairi Abdullah, Alrehili Abdulraouf, Albalawi Areej, Aldhafiri Ahmed
Drug Information Centre, Specialized Psychiatric Hospital in King Salman Bin Abdulaziz Medical City, Medina 42319, Saudi Arabia.
Pharmacy Department, Specialized Psychiatric Hospital in King Salman Bin Abdulaziz Medical City, Medina 42319, Saudi Arabia.
Pharmacy (Basel). 2024 Jun 12;12(3):92. doi: 10.3390/pharmacy12030092.
Agranulocytosis represents a severe complication associated with the administration of clozapine. Clozapine is an antipsychotic medication that has demonstrated substantial efficacy in remediating refractory schizophrenia and various other psychiatric disorders. Nonetheless, it is crucial to monitor patients for neutropenia regularly during clozapine therapy. Therefore, this article aimed to delve into the prevalence of agranulocytosis during clozapine treatment by scrutinizing the extant literature to discern trends and correlations. This review endeavored to explore factors such as drug interactions, dose-related factors, duration of treatment, and genetic predispositions that could potentially influence the likelihood of patients developing agranulocytosis while undergoing clozapine therapy. Moreover, this review enunciates the ramifications of agranulocytosis on both patients and healthcare providers and meticulously evaluates the strategies to mitigate this risk and ensure optimal patient outcomes.
粒细胞缺乏症是与使用氯氮平相关的一种严重并发症。氯氮平是一种抗精神病药物，已证明在治疗难治性精神分裂症和其他各种精神障碍方面具有显著疗效。尽管如此，在氯氮平治疗期间定期监测患者的中性粒细胞减少情况至关重要。因此，本文旨在通过审视现有文献以辨别趋势和相关性，深入研究氯氮平治疗期间粒细胞缺乏症的患病率。本综述力图探讨药物相互作用、剂量相关因素、治疗持续时间和遗传易感性等因素，这些因素可能潜在影响患者在接受氯氮平治疗时发生粒细胞缺乏症的可能性。此外，本综述阐明了粒细胞缺乏症对患者和医疗服务提供者的影响，并精心评估降低此风险并确保患者获得最佳治疗结果的策略。
